{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:51:07Z","timestamp":1771624267862,"version":"3.50.1"},"reference-count":50,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>We evaluated the associations between time-varying methotrexate (MTX) use and risk of cardiovascular events (CVE) in patients with rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We studied an inception cohort of 23,994 patients with RA diagnosed after their 65th birthday. Multivariable Cox regression models were fit to evaluate the associations between time-varying MTX use, controlling for other risk factors, and time to CVE. Alternative models assessed the cumulative duration of MTX use over the (1) first year, (2) previous year (recent use), and (3) entire duration of followup. We also assessed whether the strength of the association varied over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Over 115,453 patient-years (PY), 3294 (13.7%) patients experienced a CVE (28.5 events per 1000 PY; 95% CI 27.6\u201329.5). In the multivariable analyses, the model assessing time-varying continuous use in the most recent year yielded the best fit. Increasing recent MTX use was associated with lower CVE risks (HR 0.79 for continuous use vs no use in past 12 months, 95% CI 0.70\u20130.88; p &lt; 0.0001). Greater MTX use in the first year after cohort entry was also protective (HR 0.84, 95% CI 0.72\u20130.96; p = 0.0048), but this effect decreased with increasing followup. In contrast, longer MTX use during the entire followup was not clearly associated with CVE risk (HR 0.98, 95% CI 0.95\u20131.01; p = 0.1441).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>We observed about a 20% decrease in CVE associated with recent continuous MTX use. Greater MTX use in the first year of cohort entry also appeared to be important in the association between MTX and CVE risk.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.180427","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T17:25:10Z","timestamp":1543685110000},"page":"467-474","source":"Crossref","is-referenced-by-count":32,"title":["Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis"],"prefix":"10.3899","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-0460","authenticated-orcid":false,"given":"Jessica","family":"Widdifield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-3952","authenticated-orcid":false,"given":"Michal","family":"Abrahamowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-1714","authenticated-orcid":false,"given":"J. Michael","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9148-1038","authenticated-orcid":false,"given":"Anjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-190X","authenticated-orcid":false,"given":"J. Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3370-0006","authenticated-orcid":false,"given":"Bindee","family":"Kuriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-0157","authenticated-orcid":false,"given":"Marie-Eve","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-2802","authenticated-orcid":false,"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"key":"2019050109251918000_46.5.467.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200726"},{"key":"2019050109251918000_46.5.467.2","doi-asserted-by":"crossref","unstructured":"Widdifield J Paterson JM Huang A Bernatsky S . Causes of death in rheumatoid arthritis: How do they compare to the general population? Arthritis Care Res 2018 Mar 7 (E-pub ahead of print).","DOI":"10.1002\/acr.23548"},{"key":"2019050109251918000_46.5.467.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.20306"},{"key":"2019050109251918000_46.5.467.4","doi-asserted-by":"publisher","DOI":"10.1186\/ar2383"},{"key":"2019050109251918000_46.5.467.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.050377"},{"key":"2019050109251918000_46.5.467.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv461"},{"key":"2019050109251918000_46.5.467.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.004"},{"key":"2019050109251918000_46.5.467.8","first-page":"943","article-title":"Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis","volume":"34","author":"Dessein","year":"2007","journal-title":"J Rheumatol"},{"key":"2019050109251918000_46.5.467.9","doi-asserted-by":"crossref","first-page":"574817","DOI":"10.1155\/2012\/574817","article-title":"Genetic markers of cardiovascular disease in rheumatoid arthritis","volume":"2012","author":"Rodriguez-Rodriguez","year":"2012","journal-title":"Mediators Inflamm"},{"key":"2019050109251918000_46.5.467.10","first-page":"2957","article-title":"Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2019050109251918000_46.5.467.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206624"},{"key":"2019050109251918000_46.5.467.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.054"},{"key":"2019050109251918000_46.5.467.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep366"},{"key":"2019050109251918000_46.5.467.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151212"},{"key":"2019050109251918000_46.5.467.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203130"},{"key":"2019050109251918000_46.5.467.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207526"},{"key":"2019050109251918000_46.5.467.17","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X11436239"},{"key":"2019050109251918000_46.5.467.18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12927\/hcq.2015.24439","article-title":"Rheumatoid arthritis surveillance in Ontario: monitoring the burden, quality of care and patient outcomes through linkage of administrative health data","volume":"18","author":"Widdifield","year":"2015","journal-title":"Healthc Q"},{"key":"2019050109251918000_46.5.467.19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-216"},{"key":"2019050109251918000_46.5.467.20","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.123839"},{"key":"2019050109251918000_46.5.467.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.07.676"},{"key":"2019050109251918000_46.5.467.22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.24095\/hpcdp.30.4.06","article-title":"Myocardial infarction and the validation of physician billing and hospitalization data using electronic medical records","volume":"30","author":"Tu","year":"2010","journal-title":"Chronic Dis Can"},{"key":"2019050109251918000_46.5.467.23","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3182329778"},{"key":"2019050109251918000_46.5.467.24","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.111958"},{"key":"2019050109251918000_46.5.467.25","doi-asserted-by":"crossref","unstructured":"Abrahamowicz M Tamblyn R . Drug utilization patterns. In: Armitage P Colton T , editors. Encyclopedia of biostatistics. 2nd ed. Chichester: John Wiley & Sons; 2005:1533\u201353.","DOI":"10.1002\/0470011815.b2a04017"},{"key":"2019050109251918000_46.5.467.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.01.021"},{"key":"2019050109251918000_46.5.467.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110587"},{"key":"2019050109251918000_46.5.467.28","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4343"},{"key":"2019050109251918000_46.5.467.29","doi-asserted-by":"publisher","DOI":"10.2307\/2291569"},{"key":"2019050109251918000_46.5.467.30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/pds.3485","article-title":"Evidence of subgroup-specific treatment effect in the absence of an overall effect: Is there really a contradiction?","volume":"22","author":"Abrahamowicz","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019050109251918000_46.5.467.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019828"},{"key":"2019050109251918000_46.5.467.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093690"},{"key":"2019050109251918000_46.5.467.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.12.008"},{"key":"2019050109251918000_46.5.467.34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4372","article-title":"Methods for time-varying exposure related problems in pharmacoepidemiology: An overview","volume":"27","author":"Pazzagli","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019050109251918000_46.5.467.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110318"},{"key":"2019050109251918000_46.5.467.36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/acr.21643","article-title":"Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study","volume":"64","author":"De Vera","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2019050109251918000_46.5.467.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.142455"},{"key":"2019050109251918000_46.5.467.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.34524"},{"key":"2019050109251918000_46.5.467.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq295"},{"key":"2019050109251918000_46.5.467.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.21521"},{"key":"2019050109251918000_46.5.467.41","first-page":"69","article-title":"The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis","volume":"33","author":"Lv","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2019050109251918000_46.5.467.42","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12415"},{"key":"2019050109251918000_46.5.467.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204011"},{"key":"2019050109251918000_46.5.467.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202136"},{"key":"2019050109251918000_46.5.467.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144741"},{"key":"2019050109251918000_46.5.467.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.22255"},{"key":"2019050109251918000_46.5.467.47","doi-asserted-by":"publisher","DOI":"10.1002\/art.38306"},{"key":"2019050109251918000_46.5.467.48","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21823"},{"key":"2019050109251918000_46.5.467.49","doi-asserted-by":"publisher","DOI":"10.1002\/art.22890"},{"key":"2019050109251918000_46.5.467.50","first-page":"256","article-title":"Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account","volume":"31","author":"Huscher","year":"2013","journal-title":"Clin Exp Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.180427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T13:17:22Z","timestamp":1605532642000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.180427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.3899\/jrheum.180427"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.180427","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}